Literature DB >> 29389760

Validating an Algorithm to Predict Adjacent Musculoskeletal Infections in Pediatric Patients With Septic Arthritis.

Benjamin D Welling1, Lee S Haruno, Scott B Rosenfeld.   

Abstract

BACKGROUND: Septic arthritis is frequently associated with adjacent infections including osteomyelitis and subperiosteal and intramuscular abscesses. While often clinically indiscernible from isolated septic arthritis, the diagnosis of adjacent infections is important in determining the need for additional surgical intervention. MRI has been used as the diagnostic gold standard for assessing adjacent infection. Routine MRI, however, can be resource-intensive and delay surgical treatment. In this context, there is need for additional diagnostic tools to assist clinicians in determining when to obtain preoperative MRI in children with septic arthritis. In a previous investigation by Rosenfeld et al., an algorithm, based on presenting laboratory values and symptoms, was derived to predict adjacent infections in septic arthritis. The clinical applicability of the algorithm was limited, however, in that it was built from and applied on the same population. The current study was done to address this criticism by evaluating the predictive power of the algorithm on a new patient population. QUESTIONS/PURPOSES: (1) Can a previously created algorithm used for predicting adjacent infection in septic arthritis among pediatric patients be validated in a separate population?
METHODS: Records for all pediatric patients (1-18 years old) surgically treated for suspected septic arthritis during a 3-year period were retrospectively reviewed (109 patients). Of these patients, only those with a diagnosis of septic arthritis confirmed by synovial fluid analysis were included in the study population. Patients without confirmation of septic arthritis via synovial fluid analysis, Gram stain, or culture were excluded (34 patients). Patients with absence of MRI, younger than 1 year, insufficient laboratory tests, or confounding concurrent illnesses also were excluded (18 patients), resulting in a total of 57 patients in the study population. Five variables which previously were shown to be associated with risk of adjacent infection were collected: patient age (older than 4 years), duration of symptoms (> 3 days), C-reactive protein (> 8.9 mg/L), platelet count (< 310 x 10 cells/µL), and absolute neutrophil count (> 7.2 x 10 cells/µL). Adjacent infections were determined exclusively by preoperative MRI, with all patients in this study undergoing preoperative MRI. MR images were read by pediatric musculoskeletal radiologists and reviewed by the senior author. According to the algorithm we considered the presence of three or more threshold-level variables as a "positive" result, meaning the patient was predicted to have an adjacent infection. Comparing against the gold standard of MRI, the algorithm's accuracy was evaluated in terms of sensitivity, specificity, positive predictive value, and negative predictive value.
RESULTS: In the new population, the sensitivity and specificity of the algorithm were 86% (95% CI, 0.70-0.95) and 85% (95% CI, 0.64-0.97), respectively. The positive predictive value was determined to be 91% (95% CI, 0.78-0.97), with a negative predictive value of 77% (95% CI, 0.61-0.89). All patients meeting four or more algorithm criteria were found to have septic arthritis with adjacent infection on MRI.
CONCLUSIONS: Critical to the clinical applicability of the above-mentioned algorithm was its validation on a separate population different from the one from which it was built. In this study, the algorithm showed reproducible predictive power when tested on a new population. This model potentially can serve as a useful tool to guide patient risk stratification when determining the likelihood of adjacent infection and need of MRI. This better-informed clinical judgement regarding the need for MRI may yield improvements in patient outcomes, resource allocation, and cost. LEVEL OF EVIDENCE: Level II, diagnostic study.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29389760      PMCID: PMC5919251          DOI: 10.1007/s11999.0000000000000019

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  31 in total

1.  Septic arthritis in children: frequency of coexisting unsuspected osteomyelitis and implications on imaging work-up and management.

Authors:  Johanna Monsalve; J Herman Kan; Erica K Schallert; George S Bisset; Wei Zhang; Scott B Rosenfeld
Journal:  AJR Am J Roentgenol       Date:  2015-06       Impact factor: 3.959

2.  Anesthesia and Developing Brains - Implications of the FDA Warning.

Authors:  Dean B Andropoulos; Michael F Greene
Journal:  N Engl J Med       Date:  2017-02-08       Impact factor: 91.245

3.  Usefulness of dynamic contrast-enhanced MRI in differentiating between septic arthritis and transient synovitis in the hip joint.

Authors:  Eun Young Kim; Kyu-Sung Kwack; Jae Ho Cho; Doo-Hyung Lee; Seung-Hyun Yoon
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

4.  Clinical impact of gadolinium in the MRI diagnosis of musculoskeletal infection in children.

Authors:  J Herman Kan; Robert S Young; Chang Yu; Marta Hernanz-Schulman
Journal:  Pediatr Radiol       Date:  2010-02-24

5.  Histopathological and serological progression of experimental Staphylococcus aureus arthritis.

Authors:  T Bremell; A Abdelnour; A Tarkowski
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  The impact of the current epidemiology of pediatric musculoskeletal infection on evaluation and treatment guidelines.

Authors:  Omar A Gafur; Lawson A B Copley; S Tyler Hollmig; Richard H Browne; Lori A Thornton; Shellye E Crawford
Journal:  J Pediatr Orthop       Date:  2008 Oct-Nov       Impact factor: 2.324

7.  Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children.

Authors:  Lorna P Browne; Edward O Mason; Sheldon L Kaplan; Christopher I Cassady; Rajesh Krishnamurthy; R Paul Guillerman
Journal:  Pediatr Radiol       Date:  2008-06-17

8.  The impact of evidence-based clinical practice guidelines applied by a multidisciplinary team for the care of children with osteomyelitis.

Authors:  Lawson A B Copley; Major Alison Kinsler; Taylor Gheen; Adam Shar; David Sun; Richard Browne
Journal:  J Bone Joint Surg Am       Date:  2013-04-17       Impact factor: 5.284

9.  Infection of rabbit knee joints after intra-articular injection of Staphylococcus aureus. Comparison with joints injected with Staphylococcus albus.

Authors:  A H Johnson; W G Campbell; B C Callahan
Journal:  Am J Pathol       Date:  1970-08       Impact factor: 4.307

10.  USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children.

Authors:  Maria A Carrillo-Marquez; Kristina G Hulten; Wendy Hammerman; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

View more
  4 in total

1.  Predicting adjacent infections in pediatric septic arthritis: Do predictive criteria extrapolate across geographic regions?: Predicting Periarticular Infection in the Southeast.

Authors:  Jordan W Paynter; B Gage Griswold; Pearce W Lane; Daniel W Paré; Rahil A Patel; Michael J Steflik; K Aaron Shaw
Journal:  J Orthop       Date:  2021-11-09

2.  Point-of-care hip ultrasound leads to expedited results in emergency department patients with suspected septic arthritis.

Authors:  Christopher Thom; Azhar Ahmed; Matthew Kongkatong; James Moak
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-06-30

3.  Ten-year retrospective review of paediatric septic arthritis in a New Zealand centre.

Authors:  Sarah Hunter; Joseph F Baker
Journal:  Int Orthop       Date:  2020-08-15       Impact factor: 3.075

4.  Magnetic resonance imaging in the evaluation of suspected hip sepsis in children.

Authors:  Nicole Corin; Simon Bennet; Joshua Hill; Simon Thomas
Journal:  J Child Orthop       Date:  2022-09-27       Impact factor: 1.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.